News

STAT7h
Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
Amgen (AMGN) Stock Falls After Mixed MariTide Trial Update
Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of ...
Devdiscourse5h
Amgen Unveils MariTide's Mixed Mid-Stage Results Amid Market Concerns
Amgen's experimental drug MariTide shows potential for significant weight loss in obese patients, despite notable side ...
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously ...
American Express, Amgen share losses contribute to Dow's 100-point drop
Shares of American Express and Amgen are retreating Monday afternoon, dragging the Dow Jones Industrial Average into negative territory.
Amgen Renews Push for Colorado Payment Cap Halt At Appeals Court
Drugmaker Amgen Inc. is asking a federal appeals court to overturn a judge’s dismissal of its lawsuit seeking to prevent ...
Amgen’s Strong Cash Flow Supports Reliable Dividend Payments
Amgen Inc. (NASDAQ:AMGN) is one of the best next generation dividend aristocrat stocks. The company has built a solid track ...
Zacks Investment Research on MSN3d
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
Amgen (AMGN) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...